Publications by authors named "H W ALTMANN"
Article Synopsis
- The European LeukemiaNet (ELN) updated its risk classification for acute myeloid leukemia (AML) patients in 2022 (ELN22) and a study evaluated its effectiveness on 1,570 newly diagnosed patients.
- Compared to the previous 2017 classification (ELN17), the new ELN22 showed a similar distribution of risk categories but reclassified 22% of patients, mostly into intermediate or adverse groups, resulting in better prognostic accuracy, particularly for overall survival (OS).
- The study found significant differences in survival rates based on specific gene mutations within the adverse risk group, highlighting the need for tailored treatment approaches based on genetic factors.
Article Synopsis
- * This study aimed to validate the role of 11 specific SNPs across 6 immune-related genes in the susceptibility to infections using two independent cohorts of AML patients undergoing chemotherapy.
- * Findings revealed that certain SNPs, particularly in the DC-SIGN gene, were significantly associated with sepsis across both cohorts, while other genes like PTX3 and Dectin-1 showed links to invasive fungal disease in individual cohorts, highlighting the importance of genetic factors in managing infections in AML patients. *
Article Synopsis
- Tissue factor (TF) is part of the cytokine receptor family and plays a role in blood clotting and inflammation, but also has protective effects through unclear mechanisms.* -
- The study discovered that TF binds to the interferon-α receptor 1 (IFNAR1), inhibiting its signaling, which helps to prevent inflammation and maintain immune balance.* -
- Loss of TF specifically in kidney cells led to inflammation and immune issues, but blocking IFNAR1 signaling helped reduce these effects, suggesting the TF-IFNAR1 complex regulates thrombo-inflammation.*
Ex vivo drug response profiling is a powerful tool to study genotype-drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641 ). The primary endpoint to provide drug response profiling reports within 7 d was met in 91% of all study participants (N = 80).
View Article and Find Full Text PDFGrowth factor independence 1 (GFI1) is a DNA-binding transcription factor and a key regulator of hematopoiesis. GFI1-36N is a germ line variant, causing a change of serine (S) to asparagine (N) at position 36. We previously reported that the GFI1-36N allele has a prevalence of 10% to 15% among patients with acute myeloid leukemia (AML) and 5% to 7% among healthy Caucasians and promotes the development of this disease.
View Article and Find Full Text PDF